id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-299927-ixuvy2g4	Frontera, Jennifer	Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale	2020-05-22		.txt	text/plain	4851	229	30	As the COVID-19 pandemic evolves worldwide, reports of a spectrum of mild to severe neurological syndromes among patients infected with SARS-CoV-2 are emerging, including headache, anosmia, ageusia, seizures, coma, encephalitis, Guillain-Barre syndrome, and acute cerebrovascular events including ischemic stroke, intracerebral hemorrhage, and cerebral venous sinus thromboses [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . [15] reported that 84% (49/58) of patients with severe SARS-CoV-2 infection and acute respiratory distress syndrome had neurological symptoms including encephalopathy, agitation and confusion, and corticospinal tract signs. We established the Global Consortium to Study Neurological dysfunction in COVID-19 patients (GCS-NeuroCOVID) and promptly launched a tiered research program with an early, pragmatic, and nimble design to enable successful implementation during a global pandemic crisis when healthcare systems are stressed. The primary outcome in Tier 1 is the prevalence of new clinical neurological syndromes in SARS-CoV-2 patients including: new onset headache, anosmia/ageusia, clinical seizures/status epilepticus, strokes (ischemic and hemorrhagic), meningitis/encephalitis, hypoxic/ischemic injury, acute encephalopathy, coma, myelopathy, neuropathy, and dysautonomia/sympathetic storming.	./cache/cord-299927-ixuvy2g4.txt	./txt/cord-299927-ixuvy2g4.txt